Sign up Australia
Proactive Investors - Run By Investors For Investors

MaxCyte driving CARMA forwards

The first trading update of cell engineering specialist MaxCyte Inc (LON:MXCT) since listing on AIM was a good one, leaving founder and chief executive Doug Doerfler very confident over prospects for the current year.
Doerfler said the company had just had a very solid year in China in the financial year just ended, and the company plans to up its marketing efforts in the current year to build on this success in the People’s Republic and in other parts of the world.
The MaxCyte boss also expanded on the other main string to the company’s bow, which is the CARMA platform.
“It creates immune-based cancer treatments directly from patients’ cells,” Doerfler explained.
The platform is directing this new type of therapy towards solid tumours, in conjunction with the world-famous John Hopkins Hospital in Baltimore.
“It is a huge opportunity for the company, and a very significant unmet medical need of patients,” Doerfler told Proactive Investors.

 
Meet Great Boulder Resources Ltd, High Peak Royalties Ltd, Blackstone Minerals Ltd, Yandal Resources Ltd and Red River Resources Ltd at our event, Melbourne , 20 November 2018. Register here »
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY TO US PERSONS, AS DEFINED IN REGULATIONS PROMULGATED UNDER THE US SECURITIES ACT 1933, AS AMENDED (THE “US SECURITIES ACT”), OR IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE OR PUBLICATION WOULD BE UNLAWFUL.”
View full MXCT profile View Profile

MaxCyte Timeline

Video
November 13 2018
Article
October 10 2018

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use